Li Li

TL;DR: Rifaximin could relieve GI symptoms, modify gut microbiota in IBS-D patients and eradicate SIBO in those patients with SIBO, suggesting an additional therapeutic mechanism of rifaximIn in the treatment of IBS, and implied that altered gut microbiota were associated with the pathogenesis of Ibs.

TL;DR: The fact that claudin dysregulation correlates with increased intestinal permeability, sustained activation of inflammation, epithelial-to-mesenchymal transition (EMT), and tumor progression in IBD as well as consequent colitis-associated colorectal cancer (CAC) is elucidated, possibly shedding new light on further etiologic research and clinical treatments.

TL;DR: CBT was superior to waiting list, basic support or medical treatment at the end of treatment but not superior to other psychological treatments, and CBT was not superior in improving QOL and psychological states.

TL;DR: Owing to the importance of early treatment, simple and reliable methods for monitoring inflammatory bowel disease (IBD) are needed.